Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors

Supportive Care in Cancer

Volumn 21, Issue 12, 2013, Pages 3483-3490

  Van Den Wyngaert, T ^a   Delforge, M ^b   Doyen, C ^c   Duck, L ^d   Wouters, K ^a   Delabaye, I ^e   Wouters, C ^e   Wildiers, H ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d Clinique Saint Pierre of Ottignies   (Belgium)

^e Novartis Pharmaceuticals   (Belgium)

Author keywords

Bone metastases; Effectiveness; Long term use; Multiple myeloma; Safety; Zoledronic acid

Indexed keywords

CREATININE; ZOLEDRONIC ACID;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKELETAL RELATED EVENT; SOLID TUMOR; SPINAL CORD COMPRESSION; TOOTH PAIN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES;

EID: 84889079843     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1934-0     Document Type: Article

References (39)

1. Raje N, Roodman GD (2011) Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 17:1278-1286
2. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411-425
3. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14-27
4. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882
6. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase qI, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
7. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113:1438-1445
8. Conte P, Guarneri V (2004) Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9(Suppl 4):28-37
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
10. Cox D (1972) Regression models and life tables. J R Stat Soc Ser B 34:187-202
11. Andersen P, Gill R (1982) Cox's regression model for counting processes: a large sample study. Ann Stat 10:1100-1120
12. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306
13. Chang ST, Tenforde AS, Grimsrud CD, O'Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC (2012) Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 51:524-527
14. Bukowski R, Rosen LS, Gordon D, Tchekmedyian S, Hirsh V, Yanagihara R, Coleman RE (2003) Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer. Lung Cancer 41:262-263
15. Lipton A, Dewar R, Conte P, Zheng M (2004) Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases. Eur J Cancer Suppl 2:142-142
16. Saad F, Murray R, Venner P, Tchekmedyian S, Lacombe L, Chin J, Vinholes J, Goas JA, Zheng M (2004) Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Eur Urol Suppl 3:156-156
17. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A (2001) Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437
18. Costa L, Alho I, Semedo M, Ribeiro J, Luis I, Quintela A, Casimiro S, Leitzel K, Ali S, Lipton A (2011) Retrospective analysis of long-term bisphosphonate therapy for patients with bone metastases - bone marker profiles and safety. In 11th International conference on cancer-induced bone disease, pp. 66: Chicago, IL
19. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736
20. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472
21. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989-1999
22. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC (2012) The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol 88:1-7
23. Amadori D, Aglietta M, Alessi B (2012) ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. J Clin Oncol 30:9005
24. Coleman R, Wright J, Houston S (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30:511
25. ClinicalTrials.gov (2012) Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients (Z-MARK).
26. ClinicalTrials.gov (2012) Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer
27. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase qI, double-blind, comparative trial. Cancer J 7:377-387
28. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
29. Van den Wyngaert T, Delforge M, Doyen C, Duck L, Delabaye I, Wildiers H (2011) Renal safety of zoledronic acid in patients starting therapy and beyond 2 years of treatment - a prospective multi-center evaluation. Eur J Cancer 47:240
30. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
31. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132
32. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
33. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, CN - ASoCO (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221-1227
34. Novartis Pharmaceuticals Corporation: Zometa® (zoledronic acid) prescribing information. East Hanover, NJ, Novartis, 2008
35. Lebret T, Mouysset JL, Lortholary A, El Kouri C, Bastit L, Ktiouet M, Slimane K, Murraciole X, Guerif S (2013) Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction. Support Care Cancer 21:1613-1620
36. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18:1099-1106
37. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362
38. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19:2035-2040
39. Van den Wyngaert T, Huizing M, Vermorken J, Fossion E (2009) Bisphosphonate associated osteonecrosis of the jaw (ONJ) in cancer patients: conservative management techniques and consolidated guidelines. Int J Clin Dent 2:271-282